Dr. Andrew Limper

Dr. Andrew Limper attended the University of Illinois at Urbana-Champaign, and subsequently attended the University of Illinois, College of Medicine, graduating first in his class with induction into the Alpha Omega Alpha academic fraternity. He completed both Internal Medicine and Pulmonary-Critical Care training at the Mayo Graduate School of Medicine in Rochester, Minnesota, receiving recognition as an Outstanding Achievement Awardee of the Graduate School of Medicine. Following a research fellowship at Washington University, Dr. Limper returned to join the staff of Mayo Clinic Rochester in 1991, where he has achieved the rank of Annenberg Professor of Pulmonary Medicine. He previously served as the Chair of Pulmonary and Critical Care Medicine and as Associate Chair of the Department of Medicine for Research. Since May 2017 he has been the Associate Dean for Practice Transformation at Mayo Clinic. Dr. Limper is an expert in pulmonary fungal infections. He has authored in excess of 240 manuscripts, and has mentored dozens of trainees and junior faculty. He has held continuous NIH funding over the past 26 years, and has served as a frequent consultant to the National Institutes of Health. He is an elected member of the American Society of Clinical Investigation. He received the Distinguished Alumnus Award from his University of Illinois. Dr. Limper holds two patents related to his work in pulmonary infection, and seeks new means to diagnose and treat patients with lung infection.

Research Focus

Dr. Andrew Limper’s studies lung innate immune defense and elimination of fungal infection in patients with impaired defense systems. We seek to find new ways beyond traditional antibiotics to prevent and fight fungal lung infections in these individuals. Our work has led to the identification a novel class of drugs that both alters lung inflammation, while also strongly suppressing infection in fungal pneumonia. Our studies in Pneumocystis pneumonia and other fungal infections indicate that these agents hold significant promise and may represent an entirely new method to treat this often fatal pneumonias that occur in immune suppression that occurs in patients with malignancy, following organ transplantation and in patients with HIV/AIDS. We have additionally studied unique means to augment macrophages to more effectively eliminate fungi from the lungs while promoting tissue repair and restoration of respiratory function.